infecti
diseas
link
cancer
worldwid
among
epsteinbarr
viru
ebv
oncogen
herpesviru
chronic
infect
adult
popul
case
cancer
cancerrel
death
attribut
yearli
acut
ebv
infect
present
infecti
mononucleosi
lead
futur
onset
multipl
cancer
includ
burkitt
lymphoma
hodgkin
lymphoma
nasopharyng
carcinoma
gastric
carcinoma
mani
cancer
express
latent
viral
gene
includ
epsteinbarr
viru
nuclear
antigen
latent
membran
protein
previou
attempt
creat
potent
immunogen
ebv
report
gener
mix
success
design
novel
synthet
consensu
syncon
dna
vaccin
improv
immun
potenc
target
import
antigen
express
latent
infect
cell
ebv
tumor
antigen
hypothes
use
target
potenti
immunotherapi
ebvdriven
cancer
optim
genet
sequenc
three
antigen
studi
express
examin
immun
profil
vivo
observ
immunogen
gener
uniqu
profil
base
antigen
deliv
vaccin
target
gener
robust
cell
immun
interestingli
weak
immunogen
gener
low
level
cell
immun
standalon
vaccin
part
trival
vaccin
cocktail
abl
drive
immun
impact
ebvantigenposit
tumor
growth
studi
suggest
engin
ebv
latent
protein
vaccin
deserv
addit
studi
potenti
agent
immunotherapi
ebvdriven
cancer
vaccin
carcinoma
gastric
carcinoma
ebv
infect
also
link
autoimmun
disord
multipl
sclerosi
system
lupu
erythematosu
like
tie
ebvdriven
immun
dysregul
cancer
associ
ebv
link
express
ebv
oncogen
includ
epsteinbarr
viru
nuclear
antigen
latent
membran
protein
latent
viral
oncoprotein
ebv
import
cancer
driver
implic
directli
contribut
ebvassoci
malign
import
maintain
viral
genom
requir
ebv
latenc
associ
transform
discov
coloc
membran
latent
infect
lymphocyt
oncoprotein
contribut
cancer
progress
via
divers
signal
pathway
interact
tumor
necrosi
factor
receptor
tnfr
associ
factor
traf
drive
nuclear
mitogenactiv
protein
kinas
mapk
phosphatidylinositol
pathway
mimic
b
cell
receptor
send
surviv
signal
b
cell
without
need
antigen
stimul
gene
produc
addit
amino
acid
nterminu
approv
vaccin
avail
prevent
initi
infect
ebv
clinic
trial
ebv
vaccin
candid
limit
success
target
progress
furthest
along
clinic
recombin
subunit
prophylact
vaccin
adjuv
aluminum
hydroxid
monophosphoryl
lipid
test
phase
trial
studi
report
statist
decreas
incid
infecti
mononucleosi
vaccin
reduc
infect
viru
despit
gener
hightit
antibodi
respons
vaccin
recipi
futur
vaccin
ebv
explor
numer
glycoprotein
involv
ebv
entri
latent
protein
essenti
maintain
viru
ebv
viabl
target
therapeut
approach
treat
cancer
cellular
immun
respons
particularli
import
target
malign
cell
exploit
specif
cancer
immunotherapi
would
major
advantag
approach
would
drive
cell
respons
induc
function
cell
respons
could
clear
ebvinfect
target
prior
vaccin
approach
particularli
lack
potent
induct
cellular
immun
newer
synthet
consensu
syncon
dna
vaccin
combin
adapt
electropor
ep
demonstr
safeti
well
potent
induct
antibodi
helper
respons
effector
cell
multipl
clinic
trial
clinic
efficaci
report
context
immunotherapi
human
papillomaviru
hpv
driven
neoplasia
clinic
regress
clearanc
describ
earli
studi
use
combin
approach
involv
engin
hpv
nuclear
gene
target
checkpoint
inhibitor
therapi
specif
therapeut
dna
vaccin
target
hpv
antigen
hpv
strain
shown
posit
impact
patient
vaccin
deliv
cellectra
adapt
ep
phase
trial
treatment
cervic
intraepitheli
neoplasia
importantli
vaccin
induc
potent
cell
infiltr
tumor
caus
lesion
regress
result
histopatholog
regress
viral
clearanc
treat
patient
similar
data
report
impact
hpvdriven
head
neck
cancer
preliminari
report
similar
geneticallyadjuv
hpv
dna
vaccin
shown
drive
increas
intratumor
cell
infiltr
cell
well
result
complet
clinic
regress
metastat
head
neck
cancer
vaccin
follow
immunotherapi
outcom
observ
patient
data
support
import
synthet
dna
approach
treatment
virallydriven
cancer
reli
viral
oncogen
continu
diseas
situat
ebvdriven
cancer
well
report
studi
investig
gener
multiantigen
immunotherapeut
vaccin
ebv
infect
focus
develop
vaccin
cocktail
consist
episomemaintain
antigen
combin
two
import
latencyrel
membran
antigen
ebv
report
immun
potenc
earli
impact
combin
immun
respons
construct
epsteinbarr
viru
ebv
larg
doublestrand
dna
gammaherpesviru
kilobas
genom
encod
open
read
frame
orf
ebv
account
cancer
case
worldwid
complex
viru
ubiquit
human
popul
establish
lifelong
latent
infect
peopl
adulthood
viral
strain
divid
two
subgroup
type
type
broadli
similar
design
differ
nuclear
antigen
primari
infect
either
asymptomat
experienc
nonspecif
infect
caus
infecti
mononucleosi
latter
like
exposur
occur
adolesc
later
ebv
target
human
b
cell
transmit
oral
epithelium
via
saliva
infect
individu
establish
latenc
allow
viral
genom
persist
ebv
link
develop
sever
human
cancer
first
identifi
burkitt
lymphoma
sampl
known
caus
hodgkin
lymphoma
nasopharyng
dna
vaccin
previous
report
interest
respons
mous
model
studi
further
research
explor
immun
respons
combin
ebv
latent
protein
use
newli
design
synthet
dnaencod
antigen
studi
context
facilit
vivo
local
deliveri
result
show
potent
consist
induct
cell
immun
target
mous
model
impact
antigenposit
tumor
growth
suggest
studi
approach
ebv
immunotherapi
import
latent
protein
vaccin
consensu
sequenc
produc
sequenc
obtain
strain
codon
correspond
residu
associ
cell
signal
modifi
repetit
sequenc
delet
consensu
sequenc
avoid
inhibit
translat
mhc
class
present
alanin
mutat
made
affect
bind
similarli
mutat
made
function
domain
avoid
signal
potenti
oncogen
pathway
sequenc
codon
optim
use
syncon
technolog
prepar
vaccin
studi
within
modifi
plasmid
previous
describ
protein
extract
denatur
immunoblot
previous
describ
detect
antibodi
use
clone
biorad
hercul
ca
usa
clone
cs
abcam
cambridg
uk
polyclon
antibodi
invitrogen
carlsbad
ca
usa
secondari
antirat
mous
goat
antibodi
conjug
horseradish
peroxidas
use
visual
sigmaaldrich
st
loui
mo
usa
use
load
control
imag
captur
use
imagequantla
ge
healthcar
life
scienc
marlborough
usa
cover
slide
coat
polyllysin
cell
grow
plate
transfect
pvax
empti
vector
dna
vaccin
plasmid
use
lipofectamin
per
manufactur
protocol
invitrogen
carlsbad
ca
usa
incub
two
day
cell
wash
phosphatebuff
salin
pb
fix
paraformaldehyd
permeabil
use
triton
pb
previous
describ
commerci
antibodi
use
primari
stain
invitrogen
antimous
antirat
antigoat
secondari
antibodi
conjug
apc
use
slide
imag
use
leica
tc
confoc
laser
scan
microscop
analyz
leica
la
af
softwar
leica
microsystem
wetzlar
germani
mous
splenocyt
incub
hour
peptid
pool
compos
overlap
amino
acid
cover
full
protein
peptiv
ebv
miltenyi
biotec
bergisch
gladbach
germani
peptid
resuspend
stimul
elispot
perform
accord
manufactur
instruct
spot
count
use
cellular
technolog
limit
immunospot
analyz
previous
describ
two
million
splenocyt
cultur
hour
peptid
pool
use
previous
describ
ebiosci
protein
transport
inhibitor
cocktail
invitrogen
surfac
intracellular
remain
marker
stain
follow
biolegend
antimous
antibodi
conjug
fluorophor
use
experi
includ
livedead
exclus
perform
use
violet
fluoresc
reactiv
dye
invitrogen
data
collect
use
bd
bioscienc
lsrii
flow
cytomet
bd
bioscienc
franklin
lake
nj
usa
analyz
use
flowjo
flowjo
llc
ashland
usa
retrovirus
encod
green
fluoresc
protein
gfp
report
produc
transfect
phoenix
cell
atcc
sequenc
pbmnigfp
retroviruscontain
media
harvest
cell
use
infect
cell
spininfect
gener
tumor
cell
line
previous
describ
stabli
express
cell
express
gfp
marker
isol
use
fac
singlecel
clone
perform
obtain
clonal
cell
popul
femal
balbc
mice
purchas
jackson
lab
mice
purchas
charl
river
wistar
institut
institut
care
use
committe
approv
anim
studi
protocol
tumor
gener
inject
million
cell
axillari
region
monitor
tumor
size
thereaft
tumor
size
measur
take
longest
dimens
length
perpendicular
width
tumor
volum
calcul
use
length
width
multifoc
tumor
separ
measur
total
volum
calcul
sum
individu
volum
vaccin
introduc
dna
deliv
within
deioniz
water
intramuscular
inject
tibiali
anterior
follow
ep
cellectra
devic
inovio
pharmaceut
gener
anesthesia
use
inhal
isofluran
previous
describ
blood
collect
submandibular
bleed
postmortem
cardiac
punctur
graphpad
prism
use
perform
statist
analys
twotail
unpair
student
test
use
calcul
differ
mean
experiment
group
mannwhitney
test
nonparametr
distribut
oneway
analysi
varianc
anova
use
comparison
one
group
kruskalw
use
case
nonparametr
distribut
error
bar
graph
show
standard
error
mean
logrank
test
use
compar
surviv
rate
p
consid
statist
signific
design
consensu
optim
dna
vaccin
target
oncogen
ebv
latent
protein
commonli
seen
malign
consensu
immunogen
focu
immun
respons
toward
conserv
region
import
antigen
allow
increas
cell
cross
reactiv
well
partial
compens
minor
variabl
vaccin
target
antigen
consensu
sequenc
use
type
type
type
ebv
gene
gener
antigen
figur
optim
abil
vaccin
elicit
immun
respons
common
viral
strain
phylogenet
similar
modif
made
remov
repetit
sequenc
ablat
oncogen
properti
inher
protein
preserv
structur
antigen
figur
repetit
sequenc
remov
three
antigen
amino
acid
modifi
abrog
function
region
cell
signal
pathway
appendix
figur
phylogenet
tree
show
close
relationship
vaccin
antigen
known
sequenc
viral
isol
figur
larg
delet
made
repetit
sequenc
engin
lead
diverg
known
sequenc
long
branch
away
diagram
although
retain
sequenc
wellconserv
lmp
vaccin
lie
well
within
phylogenet
tree
demonstr
roughli
divers
conserv
support
likelihood
target
chang
elicit
immun
respons
nativ
ebv
antigen
describ
clinic
hpv
ebola
zika
howev
formal
test
anim
model
evalu
human
import
made
repetit
sequenc
engin
lead
diverg
known
sequenc
long
branch
away
diagram
although
retain
sequenc
wellconserv
lmp
vaccin
lie
well
within
phylogenet
tree
demonstr
roughli
divers
conserv
support
likelihood
target
chang
elicit
immun
respons
nativ
ebv
antigen
describ
clinic
hpv
ebola
zika
howev
formal
test
anim
model
evalu
human
import
cell
transfect
vaccin
dna
plasmid
test
express
design
synthet
dna
construct
western
blot
lysat
transfect
cell
show
band
vaccin
close
predict
molecular
weight
figur
perform
immunofluoresc
transfect
cell
evalu
express
local
construct
studi
confirm
express
protein
cell
transfect
vaccin
dna
plasmid
test
express
design
synthet
dna
construct
western
blot
lysat
transfect
cell
show
band
vaccin
close
predict
molecular
weight
figur
perform
immunofluoresc
transfect
cell
evalu
express
local
construct
studi
confirm
express
protein
show
characterist
granular
distribut
display
membran
express
figur
interestingli
found
cytoplasm
instead
typic
nuclear
local
differ
may
due
chang
consensu
sequenc
aim
avoid
sequenc
repeat
specif
chang
function
domain
affect
abil
bind
dna
suggest
encod
chang
result
attenu
vivo
immun
respons
examin
balbc
mice
anim
vaccin
either
empti
vector
individu
vaccin
antigen
combin
vaccin
incorpor
three
plasmid
group
five
mice
receiv
biweekli
vaccin
week
second
dose
sacrif
splenocyt
collect
analysi
figur
show
characterist
granular
distribut
display
membran
express
figur
interestingli
found
cytoplasm
instead
typic
nuclear
local
differ
may
due
chang
consensu
sequenc
aim
avoid
sequenc
repeat
specif
chang
function
domain
affect
abil
bind
dna
suggest
encod
chang
result
attenu
vivo
immun
respons
examin
balbc
mice
anim
vaccin
either
empti
vector
individu
vaccin
antigen
combin
vaccin
incorpor
three
plasmid
group
five
mice
receiv
biweekli
vaccin
week
second
dose
sacrif
splenocyt
collect
analysi
figur
respons
latent
protein
peptid
pool
evalu
use
elispot
assay
figur
splenocyt
mice
vaccin
gener
averag
spot
form
unit
sfu
per
million
cell
individu
vaccin
sfu
combin
tripl
vaccin
balbc
mice
insignific
differ
robust
sfu
observ
vaccin
mice
wherea
combin
vaccin
much
less
immunogen
suggest
antigen
mixtur
focu
immun
respons
gener
respons
mous
strain
individu
vaccin
combin
antigen
balbc
mice
show
sfu
individu
vaccin
sfu
combin
mice
exhibit
sfu
vax
alon
sfu
combin
produc
modest
respons
sfu
balbc
mice
notabl
combin
vaccin
observ
anim
modif
made
may
limit
immunogen
addit
engin
undertaken
enhanc
immun
antigen
modifi
construct
involv
inclus
ige
leader
sequenc
coincid
truncat
ntermin
nativ
sequenc
well
inclus
gene
fusion
tetanu
toxoid
fragment
part
orf
two
construct
made
one
short
peptid
fragment
insert
cterminu
amino
acid
fragment
insert
leader
sequenc
design
improv
immun
gener
fusion
antigen
vaccin
appendix
figur
evalu
flow
cytometri
show
cell
drive
immun
respons
figur
tripl
vaccin
gener
robust
respons
balbc
mice
greater
respons
mice
overal
respons
induc
appear
potent
induct
cell
immun
smaller
percentag
cell
induct
suggest
vaccin
cell
bias
gate
flow
cytometri
data
shown
figur
studi
immunogen
relev
outbr
anim
model
next
vaccin
mice
compar
respons
controlvaccin
anim
mice
vaccin
three
time
twoweek
interv
immun
studi
perform
week
final
vaccin
figur
cellular
respons
robust
observ
inbr
mous
model
howev
stimul
latent
protein
peptid
pool
produc
respons
measur
elispot
figur
respons
domin
splenocyt
analyz
flow
cytometri
respons
lower
figur
respons
support
potenc
vaccin
approach
order
studi
possibl
impact
ebv
tumor
express
model
antigen
next
gener
murin
epitheli
tumor
cell
line
use
cell
construct
express
use
retrovir
transduct
system
may
caus
high
express
rel
ebvassoci
tumor
cell
protein
express
cancer
cell
patient
epitop
recogn
cell
cell
line
serv
vaccin
target
immunogen
gener
select
line
shown
figur
briefli
retrovir
vector
produc
transfect
phoenix
cell
pbmn
plasmid
contain
gfp
use
stabli
transduc
cell
cell
underw
select
via
fluorescenceactiv
order
studi
possibl
impact
ebv
tumor
express
model
antigen
next
gener
murin
epitheli
tumor
cell
line
use
cell
construct
express
use
retrovir
transduct
system
may
caus
high
express
rel
ebvassoci
tumor
cell
protein
express
cancer
cell
patient
epitop
recogn
cell
cell
line
serv
vaccin
target
immunogen
gener
select
line
shown
figur
briefli
retrovir
vector
produc
transfect
phoenix
cell
pbmn
plasmid
contain
gfp
use
stabli
transduc
cell
cell
underw
select
via
fluorescenceactiv
cell
sort
fac
singlecel
clone
produc
homogen
popul
express
popul
use
introduc
tumor
mice
express
deriv
tumor
line
confirm
antibodi
reactiv
demonstr
immunofluoresc
figur
next
studi
use
cell
line
tumor
challeng
antigen
mice
receiv
either
dna
vaccin
empti
vector
three
time
biweekli
interv
follow
axillari
inject
million
tumor
cell
final
vaccin
figur
vaccin
mice
show
smaller
tumor
volum
rapid
tumor
shrinkag
vaccin
empti
vector
demonstr
antitumor
immunogen
potenti
vaccin
figur
express
deriv
tumor
line
confirm
antibodi
reactiv
demonstr
immunofluoresc
figur
next
studi
use
cell
line
tumor
challeng
antigen
mice
receiv
either
dna
vaccin
empti
vector
three
time
biweekli
interv
follow
axillari
inject
million
tumor
cell
final
vaccin
figur
vaccin
mice
show
smaller
tumor
volum
rapid
tumor
shrinkag
vaccin
empti
vector
demonstr
antitumor
immunogen
potenti
vaccin
figur
ebv
formal
known
human
gammaherpesviru
respons
infecti
mononucleosi
multipl
premalign
condit
variou
ebvdriven
cancer
cancer
includ
burkitt
lymphoma
hodgkin
lymphoma
gastric
cancer
nasopharyng
carcinoma
hivassoci
oral
hairi
leukoplakia
numer
lymphoprolif
disord
addit
ebv
infect
associ
nonmalign
diseas
signific
autoimmun
disord
worldwid
burden
ebvassoci
cancer
approxim
death
per
year
repres
almost
death
cancer
burden
continu
grow
ebvassoci
gastric
nasopharyng
carcinoma
respons
cancer
death
per
year
incid
latter
increas
light
burden
addit
approach
ebv
immunotherapi
import
engin
synthet
consensu
dna
vaccin
modifi
ebv
latent
protein
gener
immun
respons
could
impact
tumor
regress
latent
protein
present
lymphoma
carcinoma
associ
ebv
studi
potenti
target
variou
immunotherapeut
strategi
current
licens
approach
ebv
immunotherapi
cellular
therapi
studi
small
trial
shown
import
effect
howev
earli
studi
addit
approach
would
highli
benefici
along
line
work
hpv
set
syncon
dna
vaccin
deliv
adapt
ep
evolv
robust
approach
induct
antivir
cellular
immun
impact
tumor
precanc
vivo
test
approach
threeantigen
synthet
dna
vaccin
approach
target
major
ebv
latent
oncoprotein
chose
antigen
target
present
ebvassoci
cancer
small
trial
cellular
therapi
target
lmp
shown
improv
outcom
ebvassoci
diseas
high
frequenc
nasopharyng
carcinoma
concentr
east
asia
make
uniqu
environ
test
prophylact
therapeut
approach
target
viru
frequenc
hodgkin
lymphoma
europ
tempor
associ
infecti
mononucleosi
offer
anoth
opportun
grow
burden
ebv
us
suggest
immunotherapi
nasopharyng
gastric
cancer
well
associ
ebv
common
autoimmun
disord
may
also
import
consid
amen
robust
immunotherapi
approach
synthet
dna
vaccin
drive
vivo
immun
respons
via
mhc
class
ii
present
deliveri
intracellular
product
genet
encod
antigen
newer
deliveri
approach
result
gener
consist
robust
immun
target
cancer
clinic
show
design
latent
antigen
vaccin
elicit
signific
cytotox
lymphocyt
respons
encod
vaccin
target
show
domin
cell
respons
vivo
cellular
respons
import
protect
mous
model
ebv
antigenexpress
tumor
murin
vaccin
model
recent
shown
novel
heterolog
primeboost
approach
impact
tumor
challeng
importantli
immun
protect
tumor
growth
challeng
model
target
immun
immun
respons
produc
merit
studi
addit
continu
engin
may
interest
regard
dna
deliveri
immunogen
clearli
impact
tumor
growth
standalon
antigen
model
combin
develop
group
immunogen
appear
worthi
addit
attent
recent
develop
dna
platform
formul
engin
deliveri
adapt
ep
led
improv
immun
potenc
improv
consist
clinic
studi
studi
note
vaccin
bias
toward
drive
highli
desir
immun
vaccin
target
immun
bia
may
particularli
relev
clear
viral
infect
cell
cytotox
lymphocyt
induct
would
ultim
kill
tumor
cell
latent
antigen
vaccin
could
studi
context
epitheli
tumor
gastric
nasopharyng
carcinoma
among
other
addit
checkpoint
inhibitor
context
immun
report
hpv
might
also
interest
impact
ebvrel
tumor
progress
great
need
new
approach
target
ebv
licens
vaccin
immunotherapi
avail
acut
infect
lead
infecti
mononucleosi
risk
autoimmun
diseas
multipl
sclerosi
increas
follow
symptomat
infect
immunotherapi
target
conserv
express
oncogen
viral
gene
potenti
drive
immun
impact
ebvassoci
cancer
gener
synthet
dna
immunogen
target
ebv
latent
protein
engin
syncon
dna
vaccin
deliv
cellectra
ep
mice
studi
immun
respons
combin
immunogen
gener
signific
cell
respons
addit
respons
impact
tumor
growth
mous
challeng
model
studi
combin
synthet
dna
approach
ebvdriven
diseas
warrant
would
like
thank
wistar
flow
cytometri
facil
anim
facil
technic
assist
conflict
interest
dbw
receiv
sra
ownership
interest
includ
ip
perform
board
servic
inovio
receiv
sra
consult
geneon
receiv
sra
consult
geneo
serv
advisori
board
astrazeneca
sanofi
among
other
app
employe
inovio
pharmaceut
author
declar
conflict
interest
